MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable...
$251,170K
Proceeds from term loan,
net
$57,161K
Proceeds from issuance of
common stock in...
$19,653K
Proceeds from employee
stock purchase plan...
$275K
Proceeds from sale of
property and equipment
$218K
Net cash provided by
(used in) investing...
$168,520K
Net cash provided by
financing activities
$77,089K
Canceled cashflow
$82,868K
Net change in cash
and cash...
$39,169K
Canceled cashflow
$206,440K
Purchases of marketable
securities
$82,868K
Stock-based compensation
$29,876K
Accrued liabilities
$4,195K
Non-cash operating lease
expense
$1,892K
Amortization and write-off of
deferred debt issuance...
$717K
Impairment of held for sale
assets
$595K
Amortization of debt issuance
costs and accretion of...
$492K
Depreciation and
amortization
$208K
Accounts payable
$71K
Loss on disposal of
property and equipment
-$47K
Other noncash
expenses
$32K
Net cash used in
operating activities
-$206,440K
Canceled cashflow
$38,125K
Net loss
-$236,928K
Net accretion of
investments in marketable...
$2,934K
Prepaid expenses and
other current assets
$2,770K
Operating lease
liabilities
-$1,880K
Other assets
$53K
Back
Back
Cash Flow
source: myfinsight.com
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)